Anika Therapeutics (ANIK) Cash & Current Investments (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash & Current Investments data on file, last reported at $66.8 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 11.37% year-over-year to $66.8 million in Q1 2026; TTM through Mar 2026 was $66.8 million, a 11.37% decrease from a year earlier, with the FY2025 full-year figure at $81.2 million, up 2.46% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $66.8 million, down from $81.2 million in the prior quarter.
• Over the last five years, Cash & Current Investments for ANIK reached as high as $123.6 million in Q2 2022 and fell as low as $66.8 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $96.9 million across 5 years, with a median of $96.6 million in 2024.
• Across the five-year window, Cash & Current Investments soared 34.04% in 2022 and retreated 25.17% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $121.0 million in 2022, then dropped by 21.38% to $95.1 million in 2023, then dropped by 16.7% to $79.2 million in 2024, then gained by 2.46% to $81.2 million in 2025, then dropped by 17.72% to $66.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $66.8 million in Q1 2026, $81.2 million in Q4 2025, and $80.2 million in Q3 2025.